The goal of this trial is to learn if adding consolidative chemotherapy to routine chemoradiation can better control both local recurrence and metastasis and reduce the need for surgical intervention.
Subject must be able to provide study specific informed consent prior to study entry
Must be newly diagnosed, histologically proven diagnosis of adenocarcinoma of the thoracic esophagus or gastroesophageal junction (Siewert I-II);
Stage II-IVA, excluding T4b, according to the American Joint Committee on Cancer (AJCC) 8th edition;
Complete history and physical examination within 21 days of signing consent;
Cervical esophageal cancers arising 15-18 cm from the incisors.
Esophageal squamous cell carcinoma.
Patients with T4b disease according to the AJCC 8th Edition.
Definitive clinical or radiologic evidence of metastatic disease.
Duke University
Lead sponsor